Financial Data and Key Metrics Changes - The company acknowledged that its absolute performance in the quarter was unsatisfactory, but it managed to hold unit share in a category that faced greater than expected declines [6][7] - The company is experiencing a dynamic and fluid environment, making it difficult to forecast improvements in unit share for the current year, with management suggesting a more realistic outlook towards 2026 [12][13] Business Line Data and Key Metrics Changes - The company is focusing on innovation and targeting faster-growing categories to mitigate weaknesses in traditional segments, particularly in the packaged bread category [6][7] - The Wondercake innovation is reportedly pacing ahead of expectations, contributing to unit share gains, although it is still early to determine its long-term impact on the legacy cake business [16][17] Market Data and Key Metrics Changes - The company noted a premiumization trend in consumer behavior, with traditional white bread segments facing challenges due to a shift towards healthier options [13][26] - The private label segment has shown marginal improvement in market share, with total units still down but not as significantly as the overall category [53] Company Strategy and Development Direction - The company is committed to aligning its portfolio with evolving consumer tastes and investing in brand innovation to drive sustainable growth [6][7] - Management emphasized the importance of differentiation in the traditional bread segment to reinvigorate sales and address competitive pressures [14][26] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the economic environment and consumer health, indicating that improvements may take longer than previously anticipated [12][31] - The company remains confident in its long-term financial targets despite current setbacks, with plans to address health and wellness trends through innovation [26][31] Other Important Information - The company is undergoing supply chain optimization, which includes the closure of an older bakery as part of its restructuring efforts [55] - Management highlighted the introduction of smaller product sizes to cater to changing consumer needs, particularly for smaller households [57] Q&A Session Summary Question: Insights on the core packaged bread category and stabilization - Management indicated that the current environment is challenging, and while there are new business wins, significant improvement in unit share is not expected this year [11][12] Question: Details on the Wondercake innovation's impact - Management noted that it is too early to determine the long-term impact of Wondercake on the legacy cake business, but initial results are promising [16][17] Question: Changes in promotional strategy and consumer behavior - Management acknowledged an increase in promotional activity for differentiated offerings, particularly towards the end of the quarter, while maintaining a cautious approach to avoid devaluing the brand [22][23] Question: Addressing structural headwinds in the bread category - Management confirmed plans to innovate and address health and wellness trends, positioning the company as a leader in the category [26][27] Question: Impact of tariffs on guidance and cost structure - Management explained that tariff impacts are primarily affecting gross margins, with ongoing efforts to mitigate costs in selling, general, and administrative expenses [30][43] Question: Performance of private label and away-from-home business - Management reported continued weakness in foodservice sales but noted improvements in profitability and margins due to restructuring efforts [52][53]

Company Overview - Primega Group Holdings Limited is changing its ticker symbol from "PGHL" to "ZDAI" on the Nasdaq Stock Market, effective May 16, 2025, reflecting its evolving identity and strategic vision [1][3] - The company is based in the Cayman Islands and operates through its Hong Kong subsidiary, Primega Construction Engineering Co. Limited, focusing on environmentally friendly transportation services and minimizing construction waste [5] Strategic Focus - Primega Group Holdings Limited is venturing into technological advancements, including hotel marketing software development, digitized supply chain platforms, AI and IoT integration, cloud computing, and intelligent engineering equipment [2] - The new ticker symbol "ZDAI" symbolizes the company's commitment to innovation, growth, and excellence [1][3] Leadership Statement - Tan Yu, Chairman of Primega Group Holdings Limited, expressed excitement about the new ticker symbol, indicating it aligns with the company's corporate objectives and future trajectory, marking an important milestone for growth and success [3]

Summary of The Vita Coco Company (COCO) Conference Call - May 13, 2025 Company Overview - The Vita Coco Company is a market leader in the coconut water category, founded in 2004, and has a diverse product pipeline including the recently launched Vita Coco treats [2][6][12]. Industry Insights - The coconut water category is experiencing significant growth, with a reported category growth of 23% and Vita Coco brand growth of 20% in Q1 [6][12]. - The company aims to establish coconut water as a household staple across North America and other markets [7][12]. Consumer Trends - Consumer focus on health and wellness is driving demand, with consumers willing to pay for these benefits [7][10]. - The Hispanic consumer segment is a key demographic for Vita Coco, with a strong index of 60% among this group, indicating a more affluent and health-conscious consumer base [10][12]. Growth Strategy - The company plans to double its business in the next four to six years by increasing household penetration and expanding distribution channels [13][14]. - Growth drivers include increasing household usage occasions for coconut water, such as smoothies, cocktails, and hydration [15][16]. Financial Performance - Q1 results showed a 17% top-line growth, with guidance for the year set at 8% to 10% growth, driven by mid to high teens growth in coconut water [19][20]. - The company anticipates continued growth despite some losses in regional private label business [23][30]. Pricing and Tariffs - A small price increase was implemented, and further pricing adjustments are planned for Q3, influenced by a 10% baseline tariff affecting 60% of global COGS [33][35][36]. - The company is exploring ways to mitigate tariff impacts through pricing strategies and supply chain adjustments [84][86]. Distribution and Retail Relationships - Vita Coco is working to improve its distribution at Walmart, moving to a more prominent shelf space in the juice aisle, which is expected to drive future growth [42][49]. - Despite a 50% decline in distribution at Walmart, the company is gaining distribution in other channels, including convenience stores and food service [52][55]. Innovation and Product Development - The introduction of multipacks has been a significant innovation, now accounting for 50% of volume, and is expected to continue driving growth [63][64]. - The company is also focusing on expanding its product offerings, including coconut milk and treats, which are attracting new consumer segments [61][62]. International Expansion - The international segment is seen as a growth opportunity, particularly in Western Europe, where the company is investing in marketing and distribution [69][70][73]. - The UK and Germany markets are highlighted as areas of significant growth potential [70][72]. Gross Margin Outlook - Gross margins expanded in Q1, with guidance maintained for the year despite pressures from ocean freight rates and product costs [74][75]. - The company aims for long-term gross margins to approach 40%, driven by a shift from private label to branded products and successful innovation [94][96]. Marketing and SG&A - SG&A expenses are expected to grow in the low to mid-single digits, with a focus on marketing to drive brand awareness in the coconut water category [98][100]. Food Service Opportunities - The company is expanding its presence in the food service sector, targeting partnerships with coffee shops and restaurants to increase usage occasions for coconut water [101][102]. M&A Strategy - While M&A is not seen as essential for growth, the company is open to acquiring brands that align with its health and wellness focus, provided they are at the right valuation [105][110][112].

Summary of Avanos Medical (AVNS) Conference Call - May 13, 2025 Company Overview - **Company**: Avanos Medical (AVNS) - **Industry**: Consumer Goods, specifically in health and hygiene products Key Points and Arguments Company Evolution and Strategy - The company has evolved from being perceived as a "pulp proxy" to focusing on volume mix-led growth, aided by a reorganization in the previous year [3][9] - The CEO highlighted the importance of innovation and the need to elevate and expand product categories, particularly in emerging markets [11][13] - Organic growth improved from 1-2% to approximately 4% over the past five years, indicating a successful shift in strategy [14] Financial Performance and Challenges - The company faced significant cost inflation of approximately $3.5 to $3.7 billion between 2021 and 2022, impacting gross margins which fell to 29.8%, 500 basis points lower than pre-pandemic levels [31][33] - Despite challenges, the company achieved a gross margin of 36.5% in 2024, up 200 basis points year-on-year, and aims for at least 40% by the end of the decade [77] Market Dynamics - The overall category growth has decelerated to about 1.5-2%, below the historical range of 2-3%, leading to a reduction in full-year guidance primarily due to tariff impacts [51][53] - Demand for essential products remains resilient, with consumers exhibiting value-seeking behavior in developed markets [55][62] Innovation and Product Development - The company has focused on launching premium products while also ensuring competitive offerings in the value tier, with a significant shift from 60% value tier to 85% premium in North American diapers [73][74] - Recent product launches include Huggies Skin Essentials and Snug and Dry, which leverage advanced technology for better performance [101][106] Supply Chain and Cost Management - A new global supply chain organization was established to drive efficiency and standardization across product platforms [41][46] - The company is adopting a proactive risk management approach, including programmatic hedging and strategic supplier relationships to manage costs effectively [35][36] Tariff Impacts and Guidance - The company anticipates a gross impact of $300 million from tariffs, with two-thirds of this impact stemming from China [84][96] - The management is exploring ways to mitigate these costs through network reflowing and other strategies [86][90] Marketing and Advertising Strategy - The company has doubled its advertising spend since 2018, focusing on storytelling to enhance brand perception rather than relying on promotions [126][128] - The CEO expressed a preference for advertising over promotions, viewing the latter as potentially dilutive to brand value [128][129] Additional Important Insights - The company is committed to maintaining investments in innovation and brand support despite the challenging market environment [77][100] - There is a strong bifurcation in consumer behavior, with higher-income households continuing to spend on premium products while budget-constrained consumers seek value [62][65] This summary encapsulates the key discussions and insights from the Avanos Medical conference call, highlighting the company's strategic direction, financial performance, market challenges, and innovation efforts.

在"遇见深圳"企业交流环节，来自深圳的腾讯、比亚迪（002594）、荣耀、优必选等企业代表和来自日 本的伊藤忠商事、中外炉工业、松六公司相关负责人轮流发言，双方企业围绕智能装备、生物医药等产 业开展深入交流，达成多项合作意向。 在中国馆165平方米的多功能厅内，深圳市贸促会精心策划打造了"未来深圳社区的一天"交互式体验展 区。通过"清晨智慧家""午后智能公园""傍晚AI商城"三大场景，集中展示60余家深圳代表性企业在绿色 能源、智能生活、智慧康养等领域的创新成果，观众可近距离领略"深圳创造"的无限魅力，沉浸式感受 未来生活。 当天下午，由深圳市人民政府主办，市贸促会、市文体旅游局承办的"深圳-大阪创新合作大会"在大阪 帝国酒店举行，来自深圳与大阪的政府部门、商协会、企业代表等约150人参加活动。 会上，深圳航空公司代表深圳文旅开展推介。自全面升级入境旅游服务以来，深圳已陆续推出便利通 关、通信出行、跨境支付、涉外住宿、智慧游线、咨询讲解、行李运送和离境退税等一系列"深圳标 准"的服务创新，欢迎全球游客在"慢游"中品味深圳温度，共同体会深圳山海连城的景观、湾区荟萃的 精华、绚丽多彩的文化、开放包容的态度，以及敢 ...

Financial Data and Key Metrics Changes - The company reported net revenue of over $1,100,000,000 for fiscal year 2025, an increase of just over 1% compared to the prior year [6][7] - Adjusted EPS for the year was $4.52, up approximately 7% from the previous year [7][23] - Q4 revenue reached $296,500,000, a 7% increase year-over-year, with adjusted diluted EPS of $1.32, up from $1.20 in the prior year [18][19] Business Line Data and Key Metrics Changes - The North America segment saw broad-based growth, particularly in the women's health and GI categories, with brands like Summer's Eve and Dramamine performing well [18][20] - The international segment grew by 7.1% excluding foreign exchange impacts, driven by the Hydralyte brand [18][20] - E-commerce sales continued to grow at a double-digit rate, now representing high teens as a percentage of total sales [20][21] Market Data and Key Metrics Changes - The international segment experienced solid growth, particularly in Australia, contributing to overall performance [20] - E-commerce remains the fastest-growing channel, with shipment growth accelerating in Q4 [20][21] Company Strategy and Development Direction - The company emphasizes a diversified portfolio of brands to navigate market challenges and capitalize on growth opportunities [6][28] - A disciplined capital allocation strategy is in place, focusing on M&A opportunities, share repurchases, and maintaining cash reserves for future investments [25][26] - The company plans to continue leveraging its marketing agility to adapt to changing consumer preferences and market conditions [8][62] Management's Comments on Operating Environment and Future Outlook - Management highlighted ongoing challenges from tariffs, supply chain constraints, and inflation, which could impact consumer spending [5][28] - The outlook for fiscal 2026 anticipates revenues between $1,000,000,001.40 and $1,000,000,001.55, with organic growth expected at 1% to 2% [31][32] - The company expects to maintain gross margin expansion despite tariff impacts, projecting a gross margin of approximately 56.5% [21][33] Other Important Information - The company generated $243,000,000 in free cash flow for fiscal 2025, up approximately 2% from the prior year [24] - The leverage ratio improved to 2.4 times, providing strategic flexibility for capital deployment [25][26] Q&A Session Summary Question: Organic sales growth guidance of 1% to 2% - Management acknowledged macroeconomic volatility and the timing of e-commerce orders as factors influencing the guidance [35][36] Question: Recovery expectations for Clear Eyes - Management confirmed plans to expand capacity with existing suppliers and bring on new suppliers, expecting recovery in the second half of fiscal 2026 [39][41] Question: Women's health category growth outlook - Management expressed confidence in the growth of Summer's Eve and Monistat, citing successful marketing and new product launches [45][47] Question: Capital allocation strategy with reduced leverage - Management indicated a balanced approach to capital allocation, focusing on M&A opportunities while also considering share repurchases [52][54] Question: Consumer uncertainty and marketing plans - Management plans to adapt marketing strategies based on evolving consumer preferences, emphasizing the importance of needs-based products [60][62] Question: Tariff impacts and cost-saving measures - Management confirmed the $15,000,000 tariff headwind and outlined plans to mitigate costs through supplier collaboration and potential pricing adjustments [64][66] Question: E-commerce growth internationally - Management noted that e-commerce growth is primarily US-centric, with less growth observed in other markets [68] Question: Opportunities for domestic suppliers - Management is exploring opportunities for domestic sourcing to mitigate tariff impacts, particularly from China [74][76] Question: Innovation and new product launches - Management indicated a steady approach to innovation, focusing on margin-accretive products without targeting a specific percentage of sales from new products [78][80]

Financial Data and Key Metrics Changes - In Q4, the company reported sales of $193 million, exceeding the high end of guidance, with non-GAAP EPS of $0.06, above the midpoint of guidance [18] - Gross margin was 45.6%, operating margin was 9%, and adjusted EBITDA was 14.8% of sales [26] - For the full fiscal year 2025, total sales were $725 million, a decline of 31% year-over-year, with a gross margin of 48% [31] Business Line Data and Key Metrics Changes - Automotive sales increased by 8% sequentially in Q4, led by e-mobility sales which rose 16% sequentially, but declined 23% year-over-year [26] - Industrial and other sales increased by 9% sequentially, driven by growth in data center and robotics, but declined 11% year-over-year [26] - Magnetic sensor sales accounted for 61% of total sales, increasing by 3% sequentially, while power product sales increased by 19% sequentially [27] Market Data and Key Metrics Changes - Sales by geography were well balanced: 27% in China, 24% in the rest of Asia, 20% in Japan, 16% in the Americas, and 13% in Europe [28] - The company noted a 25% decline in distributor inventory levels exiting Q4 compared to the beginning of FY 2025, indicating a positive trend [25] Company Strategy and Development Direction - The company aims to accelerate new product development and expand its serviceable addressable market (SAM) to target a $12 billion market opportunity [10] - Focus areas include automotive and industrial markets, with a commitment to double-digit sales growth and maintaining gross margins of 58% or greater [17] - The company is implementing operational efficiency initiatives to enhance gross margins and profitability, including a restructuring program expected to yield annualized cost savings of at least $15 million [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering an upcycle, with positive indicators such as declining customer inventories and increasing bookings [24] - The CEO emphasized the importance of innovation and operational efficiency to drive growth and shareholder value [17][65] - Management noted that there are no abnormal pricing pressures from automotive customers related to tariffs, maintaining a normal annual cadence in negotiations [92][95] Other Important Information - The company received proposals from Onsemi for potential acquisition, which were ultimately withdrawn after the board considered them [20] - The effective tax rate for Q4 was 4%, with a full-year effective tax rate of 3%, primarily due to research and development credits [31] Q&A Session Summary Question: Update on China for China strategy - The company is making significant progress on its China for China supply chain initiative, with expectations for meaningful revenues to start shipping later in the year [41][42] Question: Gross margin outlook - The company expects to see benefits from cost reductions and restructuring initiatives impacting gross margins in Q1, with a long-term target of 58% [44][60] Question: Backlog growth and design wins - The company is seeing strong design wins in e-mobility and industrial sectors, contributing to backlog growth [50][51] Question: Inventory levels and distribution channel - Distribution channel inventories declined by 25% year-over-year, indicating a healthy inventory situation [57] Question: Competition in China - The company continues to see positive growth in China despite competition, with strong customer momentum and design wins [86][87]

Financial Data and Key Metrics Changes - The company reported net revenue of over $1,100 million, an increase of just over 1% compared to the prior year [6] - Adjusted EPS reached $4.52, up approximately 7% year-over-year [7][23] - Total company gross margin was 55.8% for fiscal 2025, up 30 basis points from the prior year, with Q4 gross margin improving to approximately 57% [21] Business Line Data and Key Metrics Changes - North America segment revenues increased by 30 basis points, while international segment revenues grew by 6.4% [20] - The women's health category, particularly the Summer's Eve brand, showed stabilization and growth, marking the second consecutive quarter of year-over-year sales growth [6][20] - The GI category, led by brands like Dramamine and Fleet, continued to experience strong performance [6][20] Market Data and Key Metrics Changes - The international segment experienced growth in excess of 5%, driven by strong performance in Australia, particularly with the Hydralyte brand [20] - E-commerce sales grew at a double-digit rate, now representing high teens as a percentage of total sales [20] Company Strategy and Development Direction - The company emphasized a disciplined capital allocation strategy, focusing on M&A opportunities, share repurchases, and building cash reserves [26] - A multi-year pipeline of new product development is in place to ensure continuous innovation and meet consumer needs [13][15] - The company plans to leverage its diverse and predominantly domestic supplier base to navigate tariff impacts and inflationary pressures [31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged heightened market volatility and consumer uncertainty due to tariffs and inflation, but expressed confidence in the company's ability to navigate these challenges [29][30] - For fiscal 2026, the company anticipates revenues between $1,000 million and $1,055 million, with organic growth forecasted at approximately 1% to 2% [32] Other Important Information - The company generated $243 million in free cash flow for fiscal 2025, up approximately 2% from the prior year [24] - The company plans to maintain a gross margin of approximately 56.5% for both fiscal 2026 and Q1 [21] Q&A Session Summary Question: Clarification on organic sales growth guidance - Management indicated that the guidance reflects macroeconomic uncertainties and the timing of e-commerce orders, which were pulled forward [36][37] Question: Recovery expectations for Clear Eyes - Management confirmed ongoing supply chain plans to expand capacity and expects a recovery in the second half of fiscal 2026 [40][41] Question: Outlook for women's health brands - Management expressed confidence in the growth potential of Summer's Eve and Monistat, supported by successful marketing and new product launches [46][48] Question: Capital allocation strategy and M&A opportunities - Management highlighted a balanced approach to capital allocation, focusing on M&A opportunities while also considering share repurchases [52][55] Question: Impact of consumer uncertainty on innovation and marketing - Management noted that needs-based categories tend to be resilient during economic uncertainty, and they will adapt marketing strategies to align with consumer preferences [60][62] Question: Tariff impacts and cost-saving measures - Management confirmed the $15 million tariff headwind and outlined plans to implement cost-saving measures while considering surgical pricing if necessary [64][66] Question: E-commerce growth internationally - Management stated that e-commerce growth remains primarily US-centric, with less growth observed in other markets [68] Question: Opportunities for domestic suppliers - Management is exploring opportunities for domestic sourcing to mitigate tariff impacts, particularly concerning products sourced from China [74][75] Question: Innovation pipeline and margin profile - Management indicated a steady impact from new products and emphasized that all innovations must be margin-accretive [77][79]

Financial Data and Key Metrics Changes - In Q4, the company reported sales of $193 million, which was above the high end of guidance, and non-GAAP EPS of $0.06, also above guidance midpoint [17][24] - Gross margin for Q4 was 45.6%, which was below expectations due to a combination of product mix and lower absorption [27] - For the full fiscal year 2025, total sales were $725 million, reflecting a decline of 31% year over year, with a gross margin of 48% [30] Business Line Data and Key Metrics Changes - Automotive sales increased by 8% sequentially in Q4, led by e-mobility sales which rose 16% sequentially, but declined 23% year over year [24][31] - Industrial and other sales increased by 9% sequentially, driven by growth in data center and robotics, but declined 11% year over year [25][31] - Magnetic sensor sales increased by 3% sequentially, accounting for 61% of total sales, while power product sales increased by 19% sequentially [26] Market Data and Key Metrics Changes - Sales by geography were well balanced, with 27% in China, 24% in the rest of Asia, 20% in Japan, 16% in the Americas, and 13% in Europe [27] - The company noted a decline in distributor inventory levels by 25% exiting Q4 compared to the beginning of FY 2025, indicating a positive trend [22] Company Strategy and Development Direction - The company aims to accelerate new product development and expand its serviceable addressable market (SAM), targeting a $12 billion market opportunity [8] - Focus on relentless innovation to drive leadership in existing and new markets, particularly in automotive and industrial sectors [8][10] - Plans to execute operational efficiency initiatives to enhance gross margins and profitability, including a restructuring program expected to yield annualized cost savings of at least $15 million [29][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering an upcycle, with positive indicators such as declining customer inventories and increasing bookings [22] - The company anticipates first-quarter sales in the range of $192 million to $200 million, representing an 18% year-over-year increase [33] - Management remains optimistic about achieving double-digit sales growth and maintaining gross margins of 58% or greater in the long term [16] Other Important Information - The company received proposals from Onsemi for potential acquisition, but Onsemi ultimately withdrew its interest [19] - The effective tax rate for Q4 was 4%, with a full-year effective tax rate of 3%, primarily due to R&D credits [30] Q&A Session Summary Question: Update on China for China strategy - The company is making significant progress on its China for China supply chain initiative, with expectations for meaningful revenues to ship later in the year [39][40] Question: Gross margin outlook - The company expects to see benefits from cost reductions and restructuring initiatives impacting gross margins in Q1, with a target to return to 50% gross margin in the near term [41][44] Question: Backlog growth and design wins - The company reported strong design wins, with over 70% in strategic focus areas, indicating a positive trend in backlog growth [47] Question: Inventory levels and distribution channel - Distribution channel inventories declined by 25% year over year, and the company is optimistic about inventory levels normalizing [55] Question: Pricing pressures and tariff impacts - The company has not seen abnormal pricing pressures or requests for additional price declines from automotive customers due to tariffs [92][93] Question: Signs of potential shortages - The company is observing potential shortages in longer lead raw materials, particularly for data center products, as demand increases [96]

Financial Data and Key Metrics Changes - IFF generated approximately $2.8 billion in sales for Q1 2025, representing a 3% comparable currency neutral growth [10] - Adjusted operating EBITDA totaled $578 million for the quarter, a strong 9% increase on a comparable currency neutral basis [10] - Comparable currency neutral adjusted operating EBITDA margin increased more than 120 basis points to 20.3% [10] Business Line Data and Key Metrics Changes - Pharma Solutions delivered $266 million in sales, an 8% year-over-year increase on a comparable currency neutral basis [11] - Taste segment sales were $627 million, a 7% year-over-year increase on a comparable currency neutral basis [13] - Food Ingredients had sales of $796 million, a 4% comparable currency neutral decrease from the prior year [13] - Health and Biosciences segment delivered a 5% increase in comparable currency neutral sales [14] - Scent achieved net sales of $614 million, up 4% year-over-year on a comparable currency neutral basis [14] Market Data and Key Metrics Changes - The company noted that broader macroeconomic dynamics remain challenging, but IFF's portfolio is grounded in resilient essential end markets [20] - The company expects approximately 2% adverse impact on revenue from foreign exchange, down from 4% previously [22] Company Strategy and Development Direction - IFF is focused on strengthening its business through consistent reinvestment in core growth drivers: R&D, commercial, digital, and capacity [20] - The company is maintaining its full-year guidance ranges despite macroeconomic uncertainties [21] - IFF completed the divestiture of Pharma Solutions, which strengthens its capital structure and helps achieve a net debt to credit adjusted EBITDA ratio of below three times [7][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the order book remaining consistent with guidance despite macroeconomic uncertainties [28] - The company is actively working with customers to mitigate impacts of tariff actions and remains disciplined in response to macroeconomic uncertainty [9] - Management acknowledged concerns about potential recessionary pressures but emphasized the resilience of 80% of its portfolio in essential products [29] Other Important Information - Cash flow from operations totaled $127 million year-to-date, with CapEx at $179 million, approximately 6% of sales [15] - Gross debt was approximately $9.3 billion, a decrease of more than $1 billion compared to the year-ago period [17] Q&A Session All Questions and Answers Question: Can you talk us through which areas of the portfolio could potentially be at risk and which parts could be more resilient in a recessionary scenario? - Management indicated that 80% of the portfolio is in essential products, which are resilient, while discretionary areas like fine fragrances may be at risk [29] Question: Can you disclose what you think the gross impact today is on your costs from tariffs? - Management noted a gross exposure of over $100 million for 2025 related to tariffs, primarily from China, but emphasized successful supply chain optimization efforts [35] Question: What were the year-ago comps for flavors and food ingredients? - Management reported that Taste grew 11% last year in Q1, while Food Ingredients declined 4% last year [40] Question: Can you elaborate on the strategic rationale for the joint venture with Chimera? - The joint venture aims to scale enzymatic biomaterials and is expected to start operations by the end of 2027, targeting high-value biodegradable polymers [44][46] Question: What drove volumes lower in protein solutions? - Management indicated that volumes were down due to weaker performance in lower-value areas and production issues in higher-value areas, which are being resolved [55] Question: How do you see the inventory cycle affecting IFF? - Management expressed that they do not believe inventory levels are elevated enough to cause a significant downtick, given the recent destocking period [88]